The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of Florida Research Foundation, Incorporated

Commonwealth Scientific and Industrial Research Organisation

The United States of America As Represented by the Department of Health

The State of Queensland, Department of Agriculture, Fisheries and Forestry

Zoetis Services LLC

The State of Queensland Acting Through the Department of Agriculture, Fisheries and Forestry

Christopher C Broder

Katharine Bossart

Yee-Peng Chan

Dimiter Stanchev Dimitrov

Michael D Boyle

Gregory Von Mering

Richard Lottenberg

Zhongyu Zhu

Bernard Moss

Patricia L Earl

Edward A Berger

Yu Feng

Paul E Kennedy

Linfa Wang

Robert W Doms

Glenn A Marsh

Hume Field

Philip M Murphy

Christophe Combadiere

Gerald Quinnan

Zhu Zhongyu

Ghalib Alkhatib

Katharine N Bossart

Jin-An Huang

Martin Elhay

Diviter S Dimitrov

The present invention relates to antibodies or antibody fragments that bind, neutralize, and/or inhibit Hendra or Nipah virus. The invention provides antibodies or antibody fragments that selectively bind to the F glycoprotein of Hendra or Nipah virus, and pharmaceutical compositions including such antibodies and/or fragments. The invention further provides polynucleotides encoding the antibodies and fragments of the invention and host cells transformed therewith. Additionally, the invention discloses prophylactic, therapeutic, and diagnostic methods employing the antibodies, fragments, polynucleotides, and/or compositions of the invention.

Antibodies against F glycoprotein of Hendra and Nipah viruses

The present disclosure is directed towards a virus, called Cedar Virus, and its methods of use.

Immunogenic Cedar Virus compositions

This invention relates to soluble forms of F glycoprotein from Hendra and Nipah virus and to compositions comprising soluble forms of F glycoprotein from Hendra and Nipah virus. This invention further relates to soluble oligomers of F glycoprotein from Hendra and Nipah virus. This invention also relates to nucleic acids encoding soluble forms of F glycoprotein from Hendra and Nipah virus. This invention also relates to diagnostic and therapeutic methods using the soluble forms of F glycoprotein from Hendra and Nipah virus. Further, this invention relates to antibodies, including neutralizing antibodies, and to vaccines for the prevention, diagnosis and treatment of infection by Hendra and Nipah viruses.

Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof

The present invention is directed towards a novel virus, called Cedar Virus, and its methods of use.

Cedar virus and methods of use

This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.

Soluble forms of Hendra and Nipah virus G glycoprotein

Soluble forms of hendra and nipah virus G glycoprotein

The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

Human monoclonal antibodies against Hendra and Nipah viruses

This invention relates to fusion polypeptides comprised of a trimerization domain fused to a non-membrane bound, non-cleaved gp160 polypeptide derived from the R2 HIV-1 Env glycoprotein and to compositions comprising the fusion polypeptides. This invention further relates to oligomers of the fusion polypeptides. This invention also relates to nucleic acids encoding the fusion polypeptides. This invention also relates to diagnostic and therapeutic methods using the fusion polypeptides. Further, this invention relates to the induction of cross-reactive neutralizing antibodies against HIV-1, and to immunogenic compositions for the prevention and treatment of infection by HIV-1.

HIV-1 envelope glycoprotein oligomer and methods of use

Human monoclonal antibodies against hendra and nipah viruses

Growing community of inventors

Silver Spring, MD, United States of America

Christopher C Broder